EUVIMEDEUVIMED entdecken
Übersichtsarbeit

A decade of advances in human gut microbiome-derived biotherapeutics

Alena L Pribyl, Philip Hugenholtz, Matthew A Cooper

Nature Microbiology · 08.01.2025 · 10 (2) · 301-312

DOI: 10.1038/s41564-024-01896-3 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Nature Microbiology, online erschienen am 08.01.2025. Verfasst von Alena L Pribyl und 2 weiteren Autor:innen. Beteiligte Einrichtung: Microba Life Sciences, Brisbane, Queensland, Australia. Hauptthemen laut MEDLINE: Gastrointestinal Microbiome, Biological Therapy. Die Arbeit wurde bisher 42-mal zitiert (Crossref) und nennt 131 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Microbiome science has evolved rapidly in the past decade, with high-profile publications suggesting that the gut microbiome is a causal determinant of human health. This has led to the emergence of microbiome-focused biotechnology companies and pharmaceutical company investment in the research and development of gut-derived therapeutics. Despite the early promise of this field, the first generation of microbiome-derived therapeutics (faecal microbiota products) have only recently been approved for clinical use. Next-generation therapies based on readily culturable and as-yet-unculturable colonic bacterial species (with the latter estimated to comprise 63% of all detected species) have not yet progressed to pivotal phase 3 trials. This reflects the many challenges involved in developing a new class of drugs in an evolving field. Here we discuss the evolution of the live biotherapeutics field over the past decade, from the development of first-generation products to the emergence of rationally designed second- and third-generation live biotherapeutics. Finally, we present our outlook for the future of this field.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Gastrointestinal MicrobiomeBiological TherapyHumansProbioticsFecal Microbiota TransplantationBacteriaFecesAnimals

Autor:innen und Institutionen

  • Microba Life Sciences, Brisbane, Queensland, Australia.
  • The University of Queensland, School of Chemistry and Molecular Biosciences, Australian Centre for Ecogenomics, Brisbane, Queensland, Australia. p.hugenholtz@uq.edu.au.
  • Sitala Bio, Cambridge, UK. m.cooper@sitala.com.

Zitieren

APA

Pribyl, A. L., Hugenholtz, P., & Cooper, M. A. (2025). A decade of advances in human gut microbiome-derived biotherapeutics. Nature Microbiology, 10(2), 301-312. https://doi.org/10.1038/s41564-024-01896-3

Vancouver

Pribyl AL, Hugenholtz P, Cooper MA. A decade of advances in human gut microbiome-derived biotherapeutics. Nature Microbiology. 2025;10(2):301-312. doi:10.1038/s41564-024-01896-3

BibTeX
@article{Pribyl2025,
  author = {Pribyl, Alena L and Hugenholtz, Philip and Cooper, Matthew A},
  title = {A decade of advances in human gut microbiome-derived biotherapeutics},
  journal = {Nature Microbiology},
  year = {2025},
  volume = {10},
  number = {2},
  pages = {301--312},
  doi = {10.1038/s41564-024-01896-3}
}
Kostenlos starten →